Navigation Links
XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain
Date:9/10/2007

Company to Hold a Conference Call Tomorrow (Tuesday) at 8:30 am EDT to

Discuss the Clinical Trial

Valley Cottage, NEW YORK, September 10 /PRNewswire-FirstCall/ -- XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB; LSE: XTL; TASE: XTL) today announced the initiation of a Phase IIb clinical trial of Bicifadine - a serotonin and norepinephrine reuptake inhibitor (SNRI) - for the treatment of diabetic neuropathic pain.

Bicifadine is being developed for the treatment of diabetic neuropathic pain which represents a significant unmet medical need in the rapidly growing multi-billion dollar neuropathic pain market. Bicifadine is a member of the SNRI drug class, a proven class in the treatment of diabetic neuropathic pain. Bicifadine's efficacy in reducing pain has been clearly demonstrated in over 15 clinical trials in acute pain, and its favorable safety profile has been established in over 3,000 patients. Importantly, Bicifadine has a unique ratio of reuptake inhibition of serotonin versus norepinephrine, which differentiates it from other members of the SNRI drug class.

The Phase IIb trial that was launched today is aimed at demonstrating the efficacy of Bicifadine in diabetic neuropathic pain, using a study design that is similar to the successful registration trials of Cymbalta(R), a member of the SNRI class that is approved for this indication, and other approved agents for neuropathic pain.

The Phase IIb study is a randomized, double-blind, placebo-controlled study comparing 200mg 3x/day (tid) and 400mg 3x/day (tid) of Bicifadine versus placebo, with a 1:1:1 randomization between the three arms, in patients with diabetic neuropathic pain. The Phase IIb study is designed to enr
'/>"/>

SOURCE XTL Biopharmaceuticals Ltd
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Protocol for RNA Isolation Using TRIzol Reagent with Phase Lock Gel-Heavy
2. Protocol for RNA Isolation Using TRIzol Reagent with Phase Lock Gel-Heavy
3. Easy preparation of total RNA from cultured cells with TRIzol and Eppendorf Phase Lock Gel
4. Identification of cells in S phase using the Cell Proliferation Fluorescence Kit and IN Cell Analyzer 1000
5. Direct Monitoring of Solid-Phase Peptide Synthesis by MALDI-TOF MS
6. Separation and Quantitation of R and S Enantiomers using Normal Phase Chromatography on an API 3000 LC/MS/MS System
7. Identification of Phase I and Phase II Metabolites of Buspirone on the Q TRAP LC/MS/MS System
8. Strategies to Identify and Confirm Phase I Metabolites of Glyburide Using the 4000 Q TRAP System
9. ANALYSIS OF AMINO ACIDS BY REVERSED PHASE CHROMATOGRAPHY WITH PRECOLUMN DERIVATISATION AND UV/VISIBLE DETECTION
10. Novel Bonding Chemistry Imparts Enhanced Polar Selectivity to TSK-GEL ODS-100V Reversed Phase Columns
11. Mobile Phase Optimization for the Analysis of an Antibody-Based Fusion Protein and Aggregates using a TSKgel Super SW3000 Size-Exclusion Column
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... GEA Niro Soavi the leader in high ... PandaPLUS 2000, which is ideal for new applications for ... disruption . This compact laboratory homogenizer is the perfect ... food additives and ingredients as well as for the ...
(Date:1/22/2015)... 22, 2015 Crystal Diagnostics (CDx) Xpress System, ... has received AOAC-PTM Certifications for the six non-O157 Shiga toxin-producing ... collectively referred to as STEC or the “Big-6”) as well ... unit (cfu) per 325 g of raw ground beef and ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Selexis SA, ... mammalian Research Cell Banks (RCBs) used for drug discovery ... Cell Banks will include Next-Generation Sequencing (NGS) ... architecture de-risks biologic manufacturing by ensuring the integrity of ...
(Date:1/22/2015)... , a precision medicine software company that has developed a ... genomic, imaging and other biomedical data in research and clinical ... CEO of Aspera, an IBM Company, to its board as ... "We are pleased to welcome Michelle to ...
Breaking Biology Technology:GEA Niro Soavi Announces the PandaPLUS 2000 Homogenizer for Processing New Applications for Nanoemulsions and Cell Disruption 2Crystal Diagnostics Awarded AOAC-PTM Accreditation for the Rapid Detection of “Big 6” E.coli Food Pathogens 2Selexis Generated Research Cell Banks Now Fully Sequenced Using Next-Generation Sequencing 2GenoSpace Expands Board with Appointment of Michelle Munson 2
... Raptor Pharmaceuticals Corp.,(OTC Bulletin Board: RPTP), today announced ... development subsidiary, will,present at the 2008 BIO International Convention ... Convention Center in San Diego, CA., Mr. Daley,s ... 2008 at 1:15p.m. (PT) in room 4 of the ...
... Skeletal Managed Care Organization Takes Prominent Position and ... at AHIP Conference, WEST SENECA, N.Y., June 11 ... announced their plans to,create a high-profile presence at a ... in San Francisco, Wednesday, June,18 to Friday, June 20, ...
... of Blockages in ... the Femoropopliteal Artery, VANCOUVER, ... TSX: ANP), a global specialty pharmaceutical and,medical device company, today ... results from the registry arm of a,clinical study measuring the ...
Cached Biology Technology:Raptor Pharmaceuticals Corp. To Present at BIO 2008 International Convention 2Raptor Pharmaceuticals Corp. To Present at BIO 2008 International Convention 3Raptor Pharmaceuticals Corp. To Present at BIO 2008 International Convention 4Palladian Muscular Skeletal Health (formerly Prism Health Networks) to Promote Collaborative, Expanded Practice Model at Major Insurance Conference in June 2Angiotech's corporate partner, Cook Medical, announces positive interim results for its Zilver(R) PTX(TM) clinical study 2Angiotech's corporate partner, Cook Medical, announces positive interim results for its Zilver(R) PTX(TM) clinical study 3Angiotech's corporate partner, Cook Medical, announces positive interim results for its Zilver(R) PTX(TM) clinical study 4Angiotech's corporate partner, Cook Medical, announces positive interim results for its Zilver(R) PTX(TM) clinical study 5
(Date:1/22/2015)... POINT ROBERTS, Washington , January 20, 2015 ... including technology and tech stocks, releases video from the CES ... and security consultant Apollo Robbins . Apollo ... the Wocket™ biometric smart wallet, a product of NXT-ID, Inc. ...
(Date:1/22/2015)... N.C. , Jan. 22, 2015 Infinisource has launched ... of the G2 model. The G2 sets a higher standard ... iSolved human capital management solution. With plug-and-play installation, touch screen ... time clock provides a robust time collection solution for the ...
(Date:12/19/2014)... , Dec. 18, 2014 Research and Markets ... the "iPhone 5S Fingerprint Sensor - Apple/AuthenTec TMDR92 ... offering. http://photos.prnewswire.com/prnh/20130307/600769 ... Apple introduced the fingerprint reading feature with the iPhone ...
Breaking Biology News(10 mins):Apollo Robbins Talks about the Illusion of Personal Safety and How Easily Your Wallet is Stolen; If a Wocket Wallet is Stolen the Thief Can't do Anything With it! 2Apollo Robbins Talks about the Illusion of Personal Safety and How Easily Your Wallet is Stolen; If a Wocket Wallet is Stolen the Thief Can't do Anything With it! 3Infinisource's NXG series sets new time clock standard 2iPhone 5S Fingerprint Sensor - Apple/AuthenTec TMDR92 & Sapphire - Technology Report 2
... BioPharma, Inc. today announced that it has begun oral dosing ... ALS-8176 is a structurally novel, anti-respiratory syncytial virus (RSV) nucleoside ... RSV infection. It is the only known nucleoside analog ... ALS-8176 demonstrates potent anti-viral activity across multiple strains of RSV ...
... uses pedometers to monitor how much people move throughout the ... a particular problem for office workers, and helping participants drop ... minutes a day, the fact that they,re sitting and not ... the day is in and of itself detrimental to their ...
... undergoing hemodialysis are known to be highly susceptible to heart ... why. New research findings published in the Journal ... are not removed by hemodialysis, increase heart attack risk. The ... an oral adsorbent called "AST-120." ...
Cached Biology News:Alios BioPharma initiates Phase 1 clinical trial for respiratory syncytial virus infection 2Study: Pedometer program helps motivate participants to sit less, move more 2
Immunogen: Extract of pigmented melanoma metastases from lymph nodes. Storage: -20 C, Avoid Freeze/Thaw Cycles...
... to Human CD66 acd Recognizes ... human neutrophils and cells in some ... reacts with transfectants containing BGPa, NCA ... members(2). Immunogen: ...
This STAT antibody sampler pack contains 8 monoclonal ,STAT antibodies....
Request Info...
Biology Products: